Want to see TSE:TLT full AI Analyst Report?

Theralase Technologies (TLT) Price & Analysis

96 Followers

TLT Stock Chart & Stats

C$0.26

>-C$0.01(-1.89%)

At close: Jul 27 4:00 PM EDT

C$0.26

>-C$0.01(-1.89%)

Day’s Range― - ―

52-Week RangeC$0.15 - C$0.41

Previous CloseN/A

Volume18.52K

Average Volume (3M)121.23K

Market Cap

C$51.74M

Enterprise ValueC$72.37

Total Cash (Recent Filing)C$1.00M

Total Debt (Recent Filing)C$431.58K

Price to Earnings (P/E)―

Beta-0.17

Next Earnings

Aug 31, 2026

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding295,671,330

10 Day Avg. Volume149,922

30 Day Avg. Volume121,227

Financial Highlights & Ratios

PEG Ratio1.28

Price to Book (P/B)23.49

Price to Sales (P/S)51.16

P/FCF Ratio-12.52

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$0.70

Price Target Upside169.23% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.01

Revenue Forecast (FY)C$802.00K

Bulls Say, Bears Say

Bulls Say

Focused Product Niche (photomedicine)Theralase's focused business model centers on laser-based medical systems and photodynamic therapy, a specialized niche with high technical barriers. This focus supports IP development, targeted clinical expertise, and clearer product roadmaps that can sustain competitive differentiation over multiple quarters.

Improving Gross MarginsGross margin rebound to roughly 51% from about 30% suggests durable improvements in product mix, pricing, or manufacturing efficiency. Higher gross margins enhance operating leverage potential as sales scale, making long-term profitability more attainable with sustained revenue growth.

Low Financial LeverageLow leverage (debt-to-equity ~0.22) and modest absolute debt give the company financial flexibility relative to many small-cap med‑tech peers. Reduced interest burden supports continued R&D and clinical programs and extends runway for strategic initiatives without immediate debt pressure.

Bears Say

Persistent Cash BurnStrongly negative operating and free cash flow (~-$3.2M TTM) demonstrates a structural cash deficit requiring recurring external financing. This increases dilution and funding risk, constrains long-term project execution, and can force prioritization or delay of commercialization initiatives.

Deep Negative ProfitabilityDeeply negative operating results and a TTM net margin near -429% indicate the cost base far exceeds current revenue. Such large losses can erode equity, limit reinvestment capacity, and require material operational or commercial inflection to reach sustainable profitability.

Small Scale And Execution/funding RiskThe company appears early-stage with limited operational scale (16 employees) and ongoing funding needs. Small size raises execution risk for regulatory, clinical, and commercial milestones, making progress sensitive to capital availability and external partnerships over the coming quarters.

Theralase Technologies News

Theralase launches up to C$5 million LIFE financing to advance cancer and antiviral pipeline

Theralase Technologies ( ($TSE:TLT) ) has issued an update. Theralase Technologies has launched a brokered private placement under...

3d ago

Theralase Grants 7 Million Stock Options to Advance Growth Plans

Theralase Technologies ( ($TSE:TLT) ) has shared an update. Theralase Technologies has granted 7,000,000 stock options to eligible...

6d ago

Theralase Posts 100% Preclinical Response in Muscle Invasive Bladder Cancer Study

Theralase Technologies ( ($TSE:TLT) ) has provided an update. Theralase Technologies reported that its X-ray-activated Rutherrin compound achieved...

4M ago

Theralase Raises C$2.66 Million to Advance Bladder Cancer Drug Programs

Theralase Technologies ( ($TSE:TLT) ) has issued an announcement. Theralase Technologies has raised C$2.66 million through a non-brokered...

4M ago

Theralase Uncovers New Antiviral Mechanism for Ruvidar Against Herpes Virus

Theralase Technologies ( ($TSE:TLT) ) just unveiled an update. Theralase Technologies has identified an additional mechanism by which...

5M ago

Theralase Raises C$1.1 Million to Advance Bladder Cancer Trial

An update from Theralase Technologies ( ($TSE:TLT) ) is now available. Theralase Technologies has closed a non-brokered private...

5M ago

Theralase’s Rutherrin Boosts Radiation Efficacy in Muscle Invasive Bladder Cancer Models

The latest update is out from Theralase Technologies ( ($TSE:TLT) ). Theralase Technologies has reported new preclinical data...

5M ago

Theralase Preclinical Data Backs Ruvidar–Interferon Combo for Bladder Cancer

An announcement from Theralase Technologies ( ($TSE:TLT) ) is now available. Theralase Technologies has reported preclinical in vitro...

5M ago

Theralase Preclinical Data Backs Ruvidar–Interferon Combo in Bladder Cancer

Theralase Technologies ( ($TSE:TLT) ) just unveiled an announcement. Theralase Technologies reported new preclinical data showing that its...

5M ago

Theralase Bladder Cancer Data Heads to Major Urology Congress as Regulatory Plans Advance

The latest announcement is out from Theralase Technologies ( ($TSE:TLT) ). Theralase Technologies’ interim clinical data for its...

6M ago

TLT FAQ

What was Theralase Technologies’s price range in the past 12 months?

Theralase Technologies lowest stock price was C$0.14 and its highest was C$0.41 in the past 12 months.

What is Theralase Technologies’s market cap?

Theralase Technologies’s market cap is C$51.74M.

When is Theralase Technologies’s upcoming earnings report date?

Theralase Technologies’s upcoming earnings report date is Aug 31, 2026 which is in 17 days.

How were Theralase Technologies’s earnings last quarter?

Currently, no data Available

Is Theralase Technologies overvalued?

According to Wall Street analysts Theralase Technologies’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Theralase Technologies pay dividends?

Theralase Technologies does not currently pay dividends.

What is Theralase Technologies’s EPS estimate?

Theralase Technologies’s EPS estimate is >-0.01.

How many shares outstanding does Theralase Technologies have?

Theralase Technologies has 295,671,330 shares outstanding.

What happened to Theralase Technologies’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Theralase Technologies?

Currently, no hedge funds are holding shares in TSE:TLT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Theralase Technologies Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

31.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Theralase Technologies

Theralase Technologies Inc. (TSX-V: TLT) is a Canada-based life sciences company focused on developing laser-based medical technologies. The company operates in photomedicine/medical devices and drug development, with a focus on photodynamic therapy (PDT) applications. Its core activities center on developing laser systems and associated light-activated therapeutic approaches for clinical use, including oncology-related indications.

Theralase Technologies (TLT) Earnings & Revenues

Historic Earnings Reports

TLT Stock 12 Month Forecast

Average Price Target

C$0.70

▲(169.23% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"C$0","1":"C$1","-1":"-C$1","-0.5":"-C$0.5","0.5":"C$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$0.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$0.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$0.70</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.285,0.3169230769230769,0.3488461538461538,0.38076923076923075,0.4126923076923077,0.4446153846153846,0.4765384615384615,0.5084615384615384,0.5403846153846154,0.5723076923076923,0.6042307692307691,0.6361538461538461,0.668076923076923,{"y":0.7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.285,0.3169230769230769,0.3488461538461538,0.38076923076923075,0.4126923076923077,0.4446153846153846,0.4765384615384615,0.5084615384615384,0.5403846153846154,0.5723076923076923,0.6042307692307691,0.6361538461538461,0.668076923076923,{"y":0.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.285,0.3169230769230769,0.3488461538461538,0.38076923076923075,0.4126923076923077,0.4446153846153846,0.4765384615384615,0.5084615384615384,0.5403846153846154,0.5723076923076923,0.6042307692307691,0.6361538461538461,0.668076923076923,{"y":0.7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.215,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.21,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.155,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.165,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.26,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.29,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.28,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.305,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.23,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.255,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.285,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >